Targeted pill trial aims to control advanced cancers by blocking key growth signals
NCT ID NCT04771520
Summary
This study is testing an oral medication called avapritinib for people with advanced solid tumors that have spread and have specific genetic changes (mutations in the CKIT or PDGFRA genes). The drug aims to block the signals that help these tumor cells grow, potentially controlling the cancer. The trial will enroll about 50 adults whose cancer has progressed on standard treatments or who have no other good options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIC LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.